Format

Send to

Choose Destination
Med Clin North Am. 2000 Jan;84(1):149-61, ix.

C-reactive protein, inflammation, and coronary risk.

Author information

1
Division of Cardiovascular Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Abstract

Data have revealed interactions between baseline concentration of hs-CRP and the efficacy of common pharmacologic therapies in primary and secondary prevention, suggesting not only that it may be possible to modify the increased risk associated with elevated hs-CRP, but also that inflammatory markers may be useful in targeting preventive therapies. Inflammatory markers may become a valuable component of routine cardiovascular risk assessment.

PMID:
10685132
DOI:
10.1016/s0025-7125(05)70211-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center